{"filings":[{"id":91719,"accession_number":"0001493152-26-021734","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 net revenue up 7% to $5.2M; net income falls to $140K; tariffs hit margins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $5.2M (+7% YoY); programmatic revenue up 23% YoY.","Net income of $140K vs $558K in Q1 2025; adjusted EBITDA $206K vs $667K.","Gross margin fell to 57% from 65%, pressured by ~$200K in tariffs and Euro strength.","Commercial mix shift (ice machines, fountains) expands addressable market but lowers near-term margins.","Cash $4.0M, no debt; conference call at 4:30pm ET today."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5212000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101984,"accession_number":"0001493152-26-013189","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2026 corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes an updated corporate presentation posted on company website on March 27, 2026.","Presentation is furnished as Exhibit 99.1; no specific financial or operational updates provided in filing.","No earnings, M&A, leadership changes, or other material events referenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118326,"accession_number":"0001493152-25-025155","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Nephros signs exclusive license & supply deal with Medica; min purchases €4.98M-€6.3M/yr through 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.","Nephros receives exclusive right to market & sell Products using Medica's Medisulfone ultrafiltration tech.","Minimum annual purchases from Medica: €4.976M (2026), €5.349M (2027), €5.750M (2028), €6.000M (2029), €6.300M (2030).","Term through Dec 31, 2030; Nephros may terminate for convenience with 90 days' notice; Medica may terminate for uncured monetary default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134767,"accession_number":"0001641172-25-022978","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 net rev $4.4M (+36% YoY); net income $237k vs loss $289k; 3rd consecutive profitable quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.4M, up 36% YoY from $3.3M; net income $237k vs net loss $289k.","Adjusted EBITDA $355k vs $(133k); gross margin improved to 63% from 59%.","Six-month net income $795k vs loss $458k; revenue $9.3M (+37% YoY).","Programmatic sales all-time high; largest dialysis filtration PO in company history.","Cash $5.1M, debt-free; active-site counts at all-time highs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":9296000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151683,"accession_number":"0001641172-25-015250","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nephros shareholders elect Lisa Nettis to board, ratify auditor, approve exec comp at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lisa Nettis elected to three-year term with 6,066,124 votes for, 84,178 withheld.","Baker Tilly US, LLP ratified as independent auditor for FY2025 with 8,663,982 for, 137,516 against.","Advisory vote on named executive officer compensation passed with 6,078,954 for, 41,762 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151682,"accession_number":"0001641172-25-009262","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 2025 revenue $4.9M (+38% YoY), net income $558K, adjusted EBITDA $667K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.9M, up 38% from $3.5M in Q1 2024; core programmatic revenue grew 23%.","Net income of $558,000 vs net loss of ($169,000) in Q1 2024; adjusted EBITDA $667,000 vs ($95,000).","Gross margin improved to 65% from 62%; record active sites of 1,600.","Cash and equivalents $4.1M, debt-free.","Management notes Q1 included elevated emergency business not expected to persist; tariff uncertainties but strong positioning."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":4877000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151681,"accession_number":"0001641172-25-006427","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alisa Lask will not stand for re-election at Nephros annual meeting on June 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alisa Lask notified the board on April 23, 2025, that she will not stand for re-election.","Her term on the board will expire at the 2025 annual meeting scheduled for June 16, 2025.","Lask's decision was not due to any disagreement with Nephros on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151680,"accession_number":"0001641172-25-001940","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2024 corporate presentation on website; no material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing announces posting of updated corporate presentation on company website.","No new financial data, guidance, or operational updates included in the 8-K.","Presentation content is not summarized; investors must review directly.","No earnings, M&A, leadership, or other material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170533,"accession_number":"0001493152-25-009390","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros reports first annual net income; Q4 revenue up 19% YoY to $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $74K for FY2024 vs net loss of $1.6M in 2023; first annual profit in company history.","Q4 net revenue $3.9M (+19% YoY); full-year revenue flat at $14.2M with core programmatic up 9% offset by emergency decline.","Gross margin improved to 62% for year (vs 59%) due to better supplier terms; SG&A down 14%.","Added nearly 600 new customer sites (~$2M sales); launched 20\" HydraGuard Ultrafilter for sterile processing market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170532,"accession_number":"0001493152-25-009035","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nephros CFO Krandel gets two stock options, bonus target raised to 30%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment to CFO Judith Krandel's letter agreement grants options for 54,359 and 58,961 shares under 2024 Equity Incentive Plan.","First option vests 25% on first anniversary, then quarterly over 3 years; second vests upon closing a strategic transaction adding ≥$4M annual revenue.","Annual performance bonus target increased to 30% of base salary; options accelerate upon termination without cause.","Grant date is 3rd business day after filing 2024 10-K; exercise price equals closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187527,"accession_number":"0001493152-24-045135","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros posts Q3 net income of $0.2M, first profitable quarter; revenue $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.5M, down 6% YoY but up 8% from Q2 2024.","Net income $0.2M vs net loss $0.2M in Q3 2023; first profitable quarter.","Adjusted EBITDA $295K vs $11K; gross margin improved to 61% from 59%.","Cash $2.5M as of Sep 30, 2024, down from $4.3M at Dec 31, 2023.","CEO cites South Central region underperformance and slower ordering from large accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":10292000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204014,"accession_number":"0001493152-24-033872","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2024 corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated 2024 Corporate Presentation made available on company website on August 26, 2024.","Presentation furnished as exhibit; no specific financial or operational metrics disclosed in the filing.","No changes to guidance, revenue, or earnings were announced in connection with this update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220706,"accession_number":"0001493152-24-021342","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nephros stockholders approve 2024 Equity Incentive Plan authorizing 2,616,875 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan adds 900,000 new shares plus prior plan reserve and returning shares; total shares authorized 2,616,875.","Stockholders elected directors Arthur H. Amron (6,860,037 for) and Oliver Spandow (6,690,864 for).","Ratified Baker Tilly US, LLP as independent auditor for FY2024 (8,545,420 for, 21,330 against).","Advisory say-on-pay approved with 6,832,340 for, 62,907 against.","Prior plan no longer available for new grants; all outstanding awards remain subject to prior terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220705,"accession_number":"0001493152-24-018435","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 revenue down 5% to $3.5M; net loss narrows to $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.5M, down 5% YoY, but programmatic (recurring non-ER) business grew 12% YoY.","Net loss improved to $0.2M from $0.3M loss in Q1 2023.","Gross margin expanded to 62% from 57%, driven by lower shipping costs and better supplier terms.","Adjusted EBITDA fell to ($95,000) from $147,000; cash decreased to $3.6M.","Launched online filter tracker; exploring nano/microplastic filtration capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":3522000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220704,"accession_number":"0001493152-24-017355","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros furnishes corporate presentation at MicroCap showcase; no material new info","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing indicates presentation at Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024.","No specific financial or operational updates are provided in the filing or exhibit.","This is a routine disclosure of investor materials; no guidance changes or material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240320,"accession_number":"0001493152-24-009216","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.","Net loss from continuing ops improved 63% to ($1.6M) for FY2023 vs ($4.3M) in 2022.","Adjusted EBITDA loss from continuing ops narrowed to ($0.1M) for FY2023, an improvement of 97%.","Cash and cash equivalents $4.3M at Dec 31, 2023; company remains debt-free.","CEO cites regulatory tailwinds from new water safety standards like ASHRAE 514 driving growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}